(12)

(11) **EP 1 757 302 A8**

CORRECTED EUROPEAN PATENT APPLICATION

published in accordance with Art. 158(3) EPC Note: Bibliography reflects the latest situation

(15) Correction information:

Corrected version no 1 (W1 A1) Bibliography INID code(s) 71, 72

(48) Corrigendum issued on: **12.12.2007 Bulletin 2007/50**

(43) Date of publication: **28.02.2007 Bulletin 2007/09**

(21) Application number: 05727594.3

(22) Date of filing: 31.03.2005

(51) Int Cl.:

A61K 38/00 (2006.01)
A61P 3/00 (2006.01)
A61P 9/00 (2006.01)
C12Q 1/02 (2006.01)

A61K 48/00 (2006.01)
A61P 3/10 (2006.01)
C12N 5/10 (2006.01)
G01N 33/15 (2006.01)

(86) International application number: **PCT/JP2005/006357**

(87) International publication number: WO 2005/094866 (13.10.2005 Gazette 2005/41)

(84) Designated Contracting States:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

(30) Priority: 31.03.2004 US 557708 P

(71) Applicants:

 TOUDAI TLO, Ltd. Tokyo 113-0033 (JP)

 Nissan Chemical Industries, Ltd. Chiyoda-ku, Tokyo 101-0054 (JP)

(72) Inventors:

 KADOWAKI, Takashi Tokyo 113-0034 (JP) YAMAUCHI, Toshimasa Tokyo 113-0024 (JP)

 KITAJIMA, Shoko c/o Mitsubishi Pharma Corporation Tokyo 103-8405 (JP)

 ITO, Yusuke c/o Biological Research Laboratories Nissan Chemical Industries, Ltd. Minamisaitama-gun, Saitama 349-0294 (JP)

(74) Representative: Dehmel, Albrecht
Dehmel & Bettenhausen
Patentanwälte,
Herzogspitalstrasse 11
80331 München (DE)

(54) ADIPONECTIN EXPRESSION INDUCER AND UTILIZATION OF THE SAME


(57) The present invention provides adiponectin expression-inducing agents, and therapeutic agents using the same for obesity and obesity-related diseases such as cardiovascular diseases or metabolic diseases, as well as methods of searching for adiponectin expression-inducing agents.

KLF9, which can bind to the 32-bp fragment of position -188 to position -157 from the adiponectin expres-

sion start site, was demonstrated to enhance adiponectin promoter activity.

Therefore, the present invention uses KLF9 as an adiponectin expression-inducing agent, and suggests that KLF9 replenishment therapy is useful for preventing and/or treating obesity or obesity-related diseases including metabolic diseases such as insulin resistance and type II diabetes, and cardiovascular diseases.

FIG. 1



Printed by Jouve, 75001 PARIS (FR)

EP 1 757 302 A8